 

Active ingredient: Aliskiren Hemifumarate 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 300 mg 




 Subjects: Healthy males and nonpregnant females, general population. 

___________________________________________________________________________ 

 

2. Type of study: Fed 

Design: single-dose, two-way crossover in-vivo 

Strength: 300 mg 

Subjects: Normal healthy males and females, general population. Females should not 
be pregnant, and if applicable, should practice abstention or contraception during the 
study. 




___________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Aliskiren in plasma 

 

Bioequivalence based on (90% CI): Aliskiren 

 

Waiver request of in-vivo testing: 150 mg based on (i) acceptable in vivo bioequivalence 
study/ies on the 300 mg strength, (ii) proportional similarity of the formulations across all 
strengths, and (iii) acceptable in vitro dissolution testing on all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD 
website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 
12 dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 

 


